Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Oct 6, 2026
- Fujifilm Installs Manufacturing Equipment for Antibody-Drug Conjugate (ADC) Components at Hirono Plant (Fujifilm)
- Aug 3, 2026
- Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Generation Antibody-Drug Conjugate (ADC) Manufacturing Technologies (Fujifilm)
- May 8, 2026
- Fujifilm Announces Approval of "SAVYSCUS® Injection" in Japan (Fujifilm)
- Dec 23, 2025
- Fujifilm Celebrates the Completion of One of the Japan’s Largest Bio CDMO Facilities in Toyama Prefecture (Fujifilm)
- Jul 24, 2025
- FUJIFILM Toyama Chemical Obtain GLP Certificate for Drug Testing with Measurement of Extracellular Field Potential (MEA method) using iPS Cell-Derived Cardiomyocyte
- May 13, 2025
- FUJIFILM Toyama Chemical Applies for Manufacturing and Marketing Approval in Japan for FF-31501, an Autologous Synovial Mesenchymal Stem Cell-based Therapy
- Apr 16, 2024
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services for mRNA therapeutics, to Provide Seamless End-to-End Services from mRNA Sequence Design to LNP Formulation and Fill/Finish
- Feb 5, 2024
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License and Supply Agreement for CleanCap® mRNA capping technology